RTW Biotech Opportunities Ltd is a venture capital fund. The fund specializes in directly investing and early-stage. The fund specializes in identifying transformative assets with high growth potential across the life sciences, biopharmaceutical and medical technology sectors. The fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.…
RTW Biotech Reports 1.1% Monthly NAV Decline As Portfolio Companies Complete IPOs
RTW Biotech Opportunities Ord (LON: RTW) is listed on the London Stock Exchange, where its shares trade in USD. It belongs to the Capital Markets industry, part of the Financial Services sector.
The shares were at 2.420 USD on 20 November 2026, up 29.8% over 52 weeks. Its 52-week range is 1.830 USD to 2.640 USD: the price is 8.3% below the high and 32.2% above the low.
At a market capitalisation of 766.75M USD, it trades at 1.9 times trailing earnings. The median trailing P/E of its 20 largest Capital Markets peers is 15.0, a discount of 87% for RTW.
RTW Biotech Opportunities Ord reports return on equity of 28.3%, an operating margin of -7.5% and revenue down 70.6% year over year.
It holds more cash than debt, a net cash position of 3.65M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.
No upcoming events tracked.